cancer inhibitors trang 4 tải miễn phí từ TAILIEUCHUNG

"cancer inhibitors" trang 4 - tải miễn phí từ Tailieuchung

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration

11 42 1

E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors

E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors

11 43 1

EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function

EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function

10 28 1

Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer

Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer

14 22 1

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma

11 44 1

Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma

Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma

10 9 1

Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review

Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review

8 78 0

$SoLAT (Sorafenib Lenvatinib alternating treatment): A new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer$

SoLAT (Sorafenib Lenvatinib alternating treatment): A new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer

12 53 1

Targeting connexin 43 with α–connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: Clinical implication for ACT1

Targeting connexin 43 with α–connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: Clinical implication for ACT1

13 26 1

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

10 37 1

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced nonsmall cell lung cancer: A systematic review and meta-analysis

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced nonsmall cell lung cancer: A systematic review and meta-analysis

17 28 1

The role of immune checkpoint inhibitor pembrolizumab in treatment of patients with non small cell lung cancer: Review

The role of immune checkpoint inhibitor pembrolizumab in treatment of patients with non small cell lung cancer: Review

7 65 0

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells

9 67 0

Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: Implications for treatment and discovery of potential therapeutic signatures

Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: Implications for treatment and discovery of potential therapeutic signatures

12 63 0

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors

10 36 0

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis

15 61 0

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors

11 15 1

AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

9 72 1

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

8 28 1

Numerical analysis of intracellular amino acid profiles of breast cancer cells with K-Ras or PI3K mutation in response to kinase inhibitors

Numerical analysis of intracellular amino acid profiles of breast cancer cells with K-Ras or PI3K mutation in response to kinase inhibitors

8 40 1

Đầu
1
2
3
[ 4 ]
5
6
7
8
9
10
11
12
13
14
Cuối

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.